# China NMPA Drug Inspection - Guangxi Lanzheng Pharmaceutical Co., Ltd. - Anti-inflammatory and choleretic tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guangxi-lanzheng-pharmaceutical-co-ltd/6b818f1d-7432-4bb6-8106-9d962fa46c47/
Source feed: China

> China NMPA drug inspection for Guangxi Lanzheng Pharmaceutical Co., Ltd. published November 08, 2019. Drug: Anti-inflammatory and choleretic tablets. The Sichuan Provincial Drug Administration released an announcement on November 8, 2019, detailing findings from its 201

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Sichuan Provincial Drug Administration's Sichuan Provincial Drug Quality Bulletin (Issue 7, 2019)
- Company Name: Guangxi Lanzheng Pharmaceutical Co., Ltd.
- Publication Date: 2019-11-08
- Drug Name: Anti-inflammatory and choleretic tablets
- Inspection Finding: The total number of mold and yeast cells did not meet the requirements.
- Action Taken: Sales and use were suspended, products were recalled, an investigation was conducted into the reasons for non-compliance, and thorough rectification was carried out. The matter was also dealt with in accordance with laws and regulations.
- Summary: The Sichuan Provincial Drug Administration released an announcement on November 8, 2019, detailing findings from its 2019 provincial drug sampling inspection program. Inspections, conducted across drug production, distribution, and usage units, identified 12 batches of non-compliant drugs. Several pharmaceutical companies were implicated, including Guangxi Qianzhen Pharmaceutical Co., Ltd., Sichuan Juyuan Pharmaceutical Group Co., Ltd., and Xichang Jingkang High-tech Technology Industry Development Co., Ltd., among others. Main violations included quality issues such as unqualified tablet core weight, excessive mold and yeast, improper content of active ingredients (e.g., Epimedium), unsatisfactory physical properties, impurities, and sulfur dioxide residue, with reference to the 2015 edition of the Chinese Pharmacopoeia. In response, the regulatory body mandated that the involved enterprises immediately suspend sales and use of the affected products, initiate recalls, investigate the root causes of the non-compliance, and implement comprehensive corrective actions to ensure rectification.

Company: https://www.globalkeysolutions.net/companies/guangxi-lanzheng-pharmaceutical-co-ltd/fa04ba19-740c-4994-a646-324b19f895c2/